Published in World J Gastroenterol on June 28, 2006
Sphincter of Oddi Function and Risk Factors for Dysfunction. Front Nutr (2017) 1.17
Use of botulinum toxin in the neurology clinic. Nat Rev Neurol (2010) 0.95
Endoscopy in the diagnosis and management of motility disorders. Dig Dis Sci (2011) 0.87
Botulinum toxin and gastrointestinal tract disorders: panacea, placebo, or pathway to the future? Gastroenterol Hepatol (N Y) (2008) 0.79
Spinal cord stimulation for intractable visceral pain due to sphincter of oddi dysfunction. Korean J Pain (2015) 0.78
Endoscopic sphincterotomy in patients with stenosis of ampulla of Vater: three-year follow-up of exocrine pancreatic function and clinical symptoms. World J Gastroenterol (2007) 0.75
Management of patients with sphincter of Oddi dysfunction based on a new classification. World J Gastroenterol (2011) 0.75
U.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci (1993) 7.98
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction. Gastroenterology (1998) 3.38
Risk factors for complications after performance of ERCP. Gastrointest Endosc (2002) 2.93
A noninvasive test of sphincter of Oddi dysfunction in postcholecystectomy patients: the scintigraphic score. J Nucl Med (1992) 2.72
Does a pancreatic duct stent prevent post-ERCP pancreatitis? A prospective randomized study. Gastrointest Endosc (2003) 2.54
Sphincter of Oddi manometry does not predispose to post-ERCP acute pancreatitis. Gastrointest Endosc (2004) 2.23
The efficacy of endoscopic sphincterotomy after cholecystectomy in patients with sphincter-of-Oddi dysfunction. N Engl J Med (1989) 2.18
Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone. Endoscopy (2002) 1.97
Endoscopic sphincterotomy-induced pancreatitis: increased risk associated with nondilated bile ducts and sphincter of Oddi dysfunction. Am J Gastroenterol (1994) 1.89
Botulinum toxin injection after biliary sphincterotomy. Endoscopy (2004) 1.76
Postcholecystectomy pain syndrome: pathophysiology of abdominal pain in sphincter of Oddi type III. Gastroenterology (1999) 1.65
Reproducibility of endoscopic sphincter of Oddi manometry. Dig Dis Sci (1991) 1.58
Idiopathic recurrent pancreatitis. An approach to diagnosis and treatment. Dig Dis Sci (1989) 1.58
Nifedipine for suspected type II sphincter of Oddi dyskinesia. Am J Gastroenterol (1993) 1.51
Use of (99m)Tc-DISIDA biliary scanning with morphine provocation for the detection of elevated sphincter of Oddi basal pressure. Gut (2000) 1.51
Comparison of sphincter of Oddi manometry, fatty meal sonography, and hepatobiliary scintigraphy in the diagnosis of sphincter of Oddi dysfunction. Gastrointest Endosc (2001) 1.47
Frequency of biliary crystals in patients with suspected sphincter of Oddi dysfunction. Gastrointest Endosc (2003) 1.46
Biopsies of the ampullary region in patients suspected to have sphincter of Oddi dysfunction. Gastrointest Endosc (1995) 1.40
Frequency of papillary dysfunction among cholecystectomized patients. Hepatology (1984) 1.40
Manometry based randomised trial of endoscopic sphincterotomy for sphincter of Oddi dysfunction. Gut (2000) 1.36
Secretin MRCP and endoscopic pancreatic manometry in the evaluation of sphincter of Oddi function: a comparative pilot study in patients with idiopathic recurrent pancreatitis. Gastrointest Endosc (2003) 1.36
Biliary dyskinesia. Endoscopy (1988) 1.34
Effect of prophylactic main pancreatic duct stenting on the incidence of biliary endoscopic sphincterotomy-induced pancreatitis in high-risk patients. Gastrointest Endosc (1993) 1.24
Sphincter of Oddi manometry in healthy volunteers. Dig Dis Sci (1990) 1.24
Frequency of abnormal sphincter of Oddi manometry compared with the clinical suspicion of sphincter of Oddi dysfunction. Am J Gastroenterol (1991) 1.20
Long-term outcome after endoscopic sphincterotomy in patients with biliary colic and suspected sphincter of Oddi dysfunction. Gastrointest Endosc (1994) 1.19
Functional disorders of the biliary tract and pancreas. Gut (1999) 1.14
Suspected sphincter of Oddi dysfunction type II: empirical biliary sphincterotomy or manometry-guided therapy? Endoscopy (2004) 1.14
Sphincter of Oddi dysfunction: results of treatment by endoscopic sphincterotomy. Br J Surg (1988) 1.14
Scintigraphy versus manometry in patients with suspected biliary sphincter of Oddi dysfunction. Gut (2003) 1.13
Do patients with sphincter of Oddi dysfunction benefit from endoscopic sphincterotomy? A 5-year prospective trial. Eur J Gastroenterol Hepatol (1996) 1.11
Effect of glyceryl trinitrate on the sphincter of Oddi motility and baseline pressure. Gut (1985) 1.10
Quantitative hepatobiliary scintigraphy and endoscopic sphincter of Oddi manometry in patients with suspected sphincter of Oddi dysfunction: assessment of flow-pressure relationship in the biliary tract. Eur J Gastroenterol Hepatol (2000) 1.09
Controlled study of the effect of nicardipine and ceruletide on the sphincter of Oddi. Gut (1992) 1.08
Long-term clinical outcome of post-cholecystectomy patients with biliary-type pain: results of manometry, non-invasive techniques and endoscopic sphincterotomy. Eur J Gastroenterol Hepatol (1996) 1.08
Sphincter of Oddi manometry: interobserver variability. Gastrointest Endosc (1993) 1.03
Incidence of pancreatitis in patients undergoing sphincter of Oddi manometry (SOM). Am J Gastroenterol (1999) 1.03
Post-cholecystectomy patients with "objective signs" of partial bile outflow obstruction: clinical characteristics, sphincter of Oddi manometry findings, and results of therapy. Gastrointest Endosc (1994) 1.02
Ampulla of Vater. Anatomic, embryologic, and surgical aspects. Surg Clin North Am (2000) 1.00
Frequency of abnormal pancreatic and biliary sphincter manometry compared with clinical suspicion of sphincter of Oddi dysfunction. Gastrointest Endosc (1999) 0.99
Endoscopic injection of botulinum toxin for biliary sphincter of Oddi dysfunction. Endoscopy (1998) 0.98
Bile duct crystals do not contribute to sphincter of Oddi dysfunction. Gastrointest Endosc (2002) 0.95
Dynamic imaging of the pancreas using real-time endoscopic ultrasonography with secretin stimulation. Gastrointest Endosc (1998) 0.92
Endoscopic sphincterotomy for stenosis of the sphincter of Oddi. Surg Endosc (2001) 0.92
Slow release nifedipine for patients with sphincter of Oddi dyskinesia: results of a pilot study. Intern Med J (2002) 0.91
Intrasphincteric injection of botulinum toxin for suspected sphincter of Oddi dysfunction. Gut (1994) 0.91
Abnormal sphincter of Oddi response to cholecystokinin in postcholecystectomy syndrome patients with irritable bowel syndrome. The irritable sphincter. Dig Dis Sci (1995) 0.90
Efficacy of nifedipine therapy in patients with sphincter of Oddi dysfunction: a prospective, double-blind, randomized, placebo-controlled, cross over trial. Br J Clin Pharmacol (1992) 0.88
Sphincter of Oddi dysfunction produces acute pancreatitis in the possum. Gut (2000) 0.88
Endoscopic injection of botulinum toxin in patients with recurrent acute pancreatitis due to pancreatic sphincter of Oddi dysfunction. Aliment Pharmacol Ther (2000) 0.88
Effects of botulinum toxin A on the sphincter of Oddi: an in vivo and in vitro study. Gut (1998) 0.86
Evaluation of endoscopic sphincterotomy in sphincter of Oddi dysfunction. Endoscopy (1992) 0.86
Comparison of ultrasound-secretin test and sphincter of Oddi manometry in patients with recurrent acute pancreatitis. Dig Dis Sci (1999) 0.84
Determination of sphincter of Oddi dysfunction in patients with prior normal manometry. Gastrointest Endosc (2003) 0.84
Advances in research and clinical practice in motor disorders of the sphincter of Oddi. J Hepatobiliary Pancreat Surg (2002) 0.83
Sphincter of oddi manometry: is it necessary to measure both biliary and pancreatic sphincter pressures? Gastrointest Endosc (2000) 0.83
Nitroester drug's effects and their antagonistic effects against morphine on human sphincter of Oddi motility. World J Gastroenterol (2005) 0.82
Sphincter of Oddi dysfunction and unexplained abdominal pain: clinical and manometric study. Dig Dis Sci (1992) 0.82
Effects of gabexate mesilate, a protease inhibitor, on human sphincter of Oddi motility. Dig Dis Sci (2002) 0.82
A synthetic prostaglandin E1 analog, alprostadil alfadex, relaxes sphincter of Oddi in humans. Dig Dis Sci (2002) 0.82
Octreotide relaxes the hypertensive sphincter of Oddi: pathophysiological and therapeutic implications. Am J Gastroenterol (2002) 0.81
Endoscopic bile duct stent placement as a predictor of outcome following endoscopic sphincterotomy in patients with suspected sphincter of Oddi dysfunction. Eur J Gastroenterol Hepatol (1997) 0.81
Cholecystokinin-Stimulated mebrofenin (99mTc-Choletec) hepatobiliary scintigraphy in asymptomatic postcholecystectomy individuals: assessment of specificity, interobserver reliability, and reproducibility. Am J Gastroenterol (2001) 0.80
The use of botulinum toxin for the treatment of gastrointestinal motility disorders. Dig Dis Sci (2004) 0.80
Electroacupuncture may relax the sphincter of Oddi in humans. Gastrointest Endosc (2001) 0.80
A controlled study of the effect of midazolam on abnormal sphincter of Oddi motility. Gastrointest Endosc (2002) 0.79
Small bowel dysmotility in patients with postcholecystectomy sphincter of Oddi dysfunction. Dig Dis Sci (1997) 0.79
The effect of equi-analgesic doses of fentanyl, morphine, meperidine and pentazocine on common bile duct pressure. Anaesthesist (1980) 0.79
Somatization disorder in sphincter of Oddi dysfunction. Psychosom Med (1997) 0.79
Prevalence of sphincter of Oddi dysfunction: can results from specialized centers be generalized? Dig Dis Sci (2002) 0.78
Visceral algesia in irritable bowel syndrome, fibromyalgia, and sphincter of oddi dysfunction, type III. Dig Dis Sci (1999) 0.78
Scintigraphic sign of functional biliary obstruction is pathognomic for sphincter of Oddi dysfunction. Hepatogastroenterology (2004) 0.78
Diazepam does not modify the motility of the sphincter of Oddi. Endoscopy (1988) 0.78
Discordance of pressure recordings from biliary and pancreatic duct segments in patients with suspected sphincter of Oddi dysfunction. Dig Dis Sci (1997) 0.77
Sphincter of Oddi dysfunction: cut and inject, but don't measure the pressure? Endoscopy (2004) 0.77
Intrasphincteric botulinum toxin type A for the diagnosis of sphincter of Oddi dysfunction: a case report. Surg Laparosc Endosc Percutan Tech (1999) 0.76
The utility of liver function test abnormalities concomitant with biliary symptoms in predicting a favorable response to endoscopic sphincterotomy in patients with presumed sphincter of Oddi dysfunction. Am J Gastroenterol (1998) 0.76
Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol (2011) 3.64
Severe muscle depletion in patients on the liver transplant wait list: its prevalence and independent prognostic value. Liver Transpl (2012) 2.26
Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transpl (2004) 1.80
Adult liver transplant survey: policies towards eligibility criteria in Canada and the United States 2007. Liver Int (2008) 1.77
Risk factors for recurrence of autoimmune hepatitis after liver transplantation. Liver Transpl (2009) 1.55
Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome. Hepatology (2002) 1.50
Allopurinol to prevent pancreatitis after endoscopic retrograde cholangiopancreatography: a randomized placebo-controlled trial. Clin Gastroenterol Hepatol (2008) 1.50
Albinterferon Alfa-2b was not inferior to pegylated interferon-α in a randomized trial of patients with chronic hepatitis C virus genotype 2 or 3. Gastroenterology (2010) 1.38
De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation (2007) 1.11
Sarcopenia as a prognostic index of nutritional status in concurrent cirrhosis and hepatocellular carcinoma. J Clin Gastroenterol (2013) 1.10
Elevated lipogenesis and diminished cholesterol synthesis in patients with hepatitis C viral infection compared to healthy humans. Hepatology (2013) 1.01
Prediction of cardiac complications after liver transplantation. Transplantation (2009) 1.00
Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus. Liver Int (2005) 0.98
The effect of 1 month of therapy with midodrine, octreotide-LAR and albumin in refractory ascites: a pilot study. Liver Int (2008) 0.98
The efficacy and safety of bile Acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus. Am J Gastroenterol (2007) 0.98
Liver transplantation for incidental cholangiocarcinoma: analysis of the Canadian experience. Liver Transpl (2005) 0.98
Polycystic liver disease: experience at a teaching hospital. Am J Gastroenterol (2005) 0.96
Prevalence of occult gastrointestinal bleeding in celiac disease. Clin Gastroenterol Hepatol (2006) 0.96
A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol (2009) 0.96
Late acute rejection after liver transplantation: the Western Canada experience. Liver Transpl (2002) 0.96
Albinterferon alfa-2b dosed every two or four weeks in interferon-naïve patients with genotype 1 chronic hepatitis C. Hepatology (2008) 0.95
Bench-to-bedside review: current evidence for extracorporeal albumin dialysis systems in liver failure. Crit Care (2007) 0.95
Liver transplantation for hepatic epithelioid hemangioendothelioma: the Canadian multicentre experience. Can J Gastroenterol (2008) 0.93
Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev (2011) 0.93
ABO-incompatible liver transplantation for critically ill adult patients. Transpl Int (2007) 0.91
Alcohol use while on the liver transplant waiting list: a single-center experience. Liver Transpl (2010) 0.88
Twelve weeks of follow-up is sufficient for the determination of sustained virologic response in patients treated with interferon alpha for chronic hepatitis C. J Hepatol (2003) 0.83
Nonalcoholic fatty liver disease in patients investigated for elevated liver enzymes. Can J Gastroenterol (2003) 0.83
Simple clinical variables predict liver histology in hepatitis C: prospective validation of a clinical prediction model. Scand J Gastroenterol (2005) 0.82
Cholangiocarcinoma: has there been any progress? Can J Gastroenterol (2010) 0.82
Autoimmune pancreatitis with autoimmune hemolytic anemia. Pancreas (2006) 0.81
Simultaneous liver and kidney transplants: optimizing use of this double resource. Transplantation (2011) 0.81
Incidence and risk factors associated with de novo autoimmune hepatitis after liver transplantation. Liver Int (2012) 0.80
A case-control study of single-pass albumin dialysis for acetaminophen-induced acute liver failure. Blood Purif (2009) 0.78
Early prediction of sustained virological response at day 3 of treatment with albinterferon-alpha-2b in patients with genotype 2/3 chronic hepatitis C. Liver Int (2009) 0.78
Increased duration of dual pegylated interferon and ribavirin therapy for genotype 1 hepatitis C post-liver transplantation increases sustained virologic response: a retrospective review. Saudi J Gastroenterol (2013) 0.78
Dramatic reduction in tumour size in hepatocellular carcinoma patients on thalidomide therapy. Can J Gastroenterol (2007) 0.75
Cardiac work-up protocol for liver transplant candidates: experience from a single liver transplant centre. Can J Gastroenterol (2012) 0.75
Hepatitis C eradication and improvement of cryoglobulinemia-associated rash and membranoproliferative glomerulonephritis with interferon and ribavirin after kidney transplantation. Can J Gastroenterol (2006) 0.75
A Canadian multicenter retrospective study evaluating transjugular liver biopsy in patients with congenital bleeding disorders and hepatitis C: is it safe and useful? Am J Hematol (2005) 0.75
Identifying HCV genotype 1 patients at risk of relapse. Eur J Gastroenterol Hepatol (2010) 0.75
An unusual cause of elevated liver enzymes in a diabetic patient. Gastroenterology (2013) 0.75
Is pre-treatment liver biopsy necessary for all hepatitis C genotypes? Ann Hepatol (2011) 0.75